Yahoo Finance: The Speak Foundation Launches Patient-Led National LGMD Centers of Excellence, Uniting Leading Academic Institutions to Accelerate Clinical Trials and New Therapies
The Speak Foundation Launches Patient-Led National LGMD Centers of Excellence, Uniting Leading Academic Institutions to Accelerate Clinical Trials and New Therapies
The Dementia Trials Accelerator has taken a significant step towards transforming dementia clinical trials in the UK by welcoming its first participants into clinics for simple tests that will ...
The traditional gold standard of clinical trials with a randomized, placebo-controlled design involving hundreds of patients has inherently been unfeasible for the rare disease community. | The ...
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 ...
Lead Pharma Announces Start of Phase I Clinical Trials with SAR441169 Candidate Treatment for Psoriasis March 21st, 2019
Jeeva Clinical Trials’ new partnership program provides researchers advanced AI tools to accelerate development of life-saving therapies.
Medicine Buffalo: FDA approves drug based on clinical trial led by UB researcher
EurekAlert!: Alliance for Clinical Trials in Oncology supports April Head and Neck Awareness Month
Alliance for Clinical Trials in Oncology supports April Head and Neck Awareness Month
Forbes: This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster
Formation Bio CEO Ben Liu is convinced that drug discovery isn’t the bottleneck in getting medicines to market—it’s going through clinical trials. Now he’s raised some $615 million from top investors ...
This Sam Altman-Backed $1.8 Billion Startup Bets AI Can Get Drugs Through Clinical Trials Faster
Business Insider: NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
Yahoo Finance: Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights
Oncolytic Virus Immunotherapy Market Landscape Report 2026: A $5 Opportunity by 2031 - Technology Platforms, Approved Therapy Dosage, Price & Clinical Trials Insights
Morningstar: Bio Behavioral Health Joins PhaseWell Research to Expand Access to Neuropsychiatric Clinical Trials
Bio Behavioral Health Joins PhaseWell Research to Expand Access to Neuropsychiatric Clinical Trials
Yahoo Finance: Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients
A landmark international clinical trial led by researchers at the Centre for Addiction and Mental Health (CAMH) and University of California San Diego School of Medicine, published in The Lancet ...
Between 2020 and 2024, the number of unique sites in the United States where phase I clinical trials for non-small cell lung cancer (NSCLC) were conducted decreased by 44% and became increasingly ...
Fierce Biotech: Small pools, big ideas: How the rare disease community is reimagining clinical trials
Small pools, big ideas: How the rare disease community is reimagining clinical trials
Lead Pharma is a clinical-stage pharmaceutical research & development company. We design and develop innovative small-molecule therapies to treat autoimmune diseases and cancer. Our team of R&D professionals offers a wealth of experience in numerous areas of drug discovery, from target identification through lead optimization to pre-clinical development. We have a proven track record of ...
R&D collaboration building on Lead Pharma’s expertise in the discovery, design and optimization of small molecule treatments Lead Pharma may receive payments of up to €260 million plus royalties on sales Lead Pharma, a clinical stage pharmaceutical company, designing and developing innovative medicines for the treatment of immune mediated diseases and cancer, today announced that it has ...
We’re delighted to announce the publication of results from our collaboration with Maarten Bijlsma and Hanneke van Laarhoven from Amsterdam UMC. The results have been published in Cell Reports Medicine, a journal with high impact for cutting-edge research in translational and clinical biomedical sciences. About the paper: Esophageal cancer is the seventh most common and
Validated biomarkers will help physicians identify patient subgroups that will benefit most from specific treatment modalities, but challenges to implementation remain.
The American Bazaar: Indian American scientist targets clinical ‘innovation gap’ with AI
Medical Xpress on MSN: Bowel cancer immunotherapy clinical trial follow-up shows zero relapses
News-Medical.Net: First participants join clinical study to fast-track dementia research in the UK
First participants join clinical study to fast-track dementia research in the UK
It is NOT 'bad' to use the new keyword. But if you forget it, you will be calling the object constructor as a regular function. If your constructor doesn't check its execution context then it won't notice that 'this' points to different object (ordinarily the global object) instead of the new instance. Therefore your constructor will be adding properties and methods to the global object ...
New does not guarantee heap allocation and simply avoiding new does not guarantee stack allocation. New is always used to allocate dynamic memory, which then has to be freed. By doing the first option, that memory will be automagically freed when scope is lost.
WASHINGTON, D.C., (GLOBE NEWSWIRE) -- NeuroRPM, a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used ...
MarketWatch: Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan
The MarketWatch News Department was not involved in the creation of this content. MIAMI, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Klothea Bio, Inc. ("Klothea Bio"), a clinical-stage biotechnology company ...
Klothea Bio Announces the Launch of a Phase 1b Clinical Trial of AKL003, an Alpha Klotho mRNA Therapeutic, for the Extension of Human Lifespan
The oncolytic virus immunotherapy market presents opportunities with three approved therapies, extensive clinical trial pipelines, and innovative research by biotechnology and pharmaceutical companies ...
MSN: Upstream Bio Initiates Phase 2 Clinical Trial for COPD Drug, Verekitug
Nasdaq: Upstream Bio Announces First Patient Dosed in Phase 2 Clinical Trial of Verekitug in Chronic Obstructive Pulmonary Disease (COPD)
– Global Phase 2 clinical trial, VENTURE, to evaluate the efficacy and safety of verekitug administered every 12 or 24 weeks in moderate-to-severe COPD – – Broadens global development program for ...